Single User License
INR 516477
Site License
INR 1032954
Corporate User License
INR 1549431

Service Tax Additional

select a format
Price

Single User License
USD 7995
Site License
USD 15990
Corporate User License
USD 23985

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


OpportunityAnalyzer: Sepsis-Opportunity Analysis and Forecasts to 2021

OpportunityAnalyzer: Sepsis-Opportunity Analysis and Forecasts to 2021


  • Products Id :- GDHC032POA
  • |
  • Pages: 255
  • |
  • March 2015
  • |
  • |
  Request for Sample Report

Executive Summary

OpportunityAnalyzer: Sepsis-Opportunity Analysis and Forecasts to 2021

Sepsis patients suffer from a series of diverse complications arising from the presence of pathogens and/or their toxins in the blood or tissues, which cause a rapidly progressing hyperactive host immune response and cellular dysfunction leading to mortality rates near 50% depending on disease severity. The syndrome places a major burden on the national healthcare systems of the global marketplace, which for the purposes of this report is comprised of the US, France, Germany, Italy, Spain, and the UK. There are currently no marketed drugs to treat sepsis and current treatment options are limited to careful monitoring, pathogen-targeting therapies, and supportive care and symptom management.

For the purposes of this report, GlobalData defines the sepsis market to include sales of sepsis-specific, host-directed products in patients 18 years and older. Therefore a detailed analysis and sales projections for antibiotics is beyond the scope of this report. The projection of annual sales for medical devices is also beyond the scope of this report, however anticipated launch dates and patient uptake estimates for these products is included in the forecast. GlobalData expects the market to experience modest growth that is primarily driven by the increased uptake of novel therapies-led by Asahi Kasei Pharma America Corporation's ART-123-in select patients as the critical care community regains confidence in sepsis-specific products and as more data is generated on their overall efficacy and safety. Primary research revealed that skepticism, cynicism, and cautious optimism towards sepsis pipeline products is related to recent high profile failures of products in clinical development.

Highlights

Key Questions Answered

Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the sepsis marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (2016-2021)?

What research and development (R&D) strategies will companies leverage to compete in the future sepsis marketplace?

Which patient population(s) are most likely to be targeted for sepsis-specific product development?

What clinical and commercial factors are likely to influence sepsis product uptake in the US and 5EU (France, Germany, Italy, Spain, and the UK)?

Key Findings

GlobalData projects the sepsis market in the US and 5EU to grow from approximately USD 26m in 2016 to USD 354m in 2021, at a compound annual growth rate (CAGR) of 69%. This solid growth will be driven by the increased uptake of novel therapies-led by AKP's anticoagulant ART-123-in select patients as the critical care community regains confidence in sepsis-specific products and more data is generated on their overall efficacy and safety.

KOLs interviewed by GlobalData were cautiously optimistic regarding the clinical benefits of pipeline products in their currently selected trial participants and reiterated further improvements are necessary in an area with major unmet medical needs.

GlobalData anticipates that firms will increasingly turn to innovative R&D strategies, in particular the exploration of alternative approaches to clinical trial design and improved patient targeting-such as adaptive design trials and companion diagnostics-in order to increase developmental efficiency, minimize upfront risk, and gain a competitive advantage over rivals.

Scope

Overview of sepsis, severe sepsis, and septic shock, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.

Topline sepsis market revenue from 2016-2021. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included*.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the sepsis market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.

Analysis of the current and future market competition in the global sepsis market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons To Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global sepsis market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the sepsis market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

1 Table of Contents

1 Table of Contents 12

1.1 List of Tables 17

1.2 List of Figures 20

2 Introduction 22

2.1 Catalyst 22

2.2 Related Reports 23

2.3 Upcoming Related Reports 24

3 Disease Overview 25

3.1 Etiology and Pathophysiology 25

3.1.1 Etiology 25

3.1.2 Pathophysiology 28

3.2 Symptoms 36

3.3 Disease Management 37

3.3.1 Diagnosis 37

3.3.2 Treatment Guidelines 38

3.3.3 Clinical Practice 41

3.4 Quality of Life Post Sepsis 43

4 Epidemiology 45

4.1 Disease Background 45

4.2 Risk Factors and Comorbidities 46

4.3 Global Trends 46

4.3.1 US 47

4.3.2 5EU 47

4.4 Forecast Methodology 48

4.4.1 Sources Used 53

4.4.2 Forecast Assumptions and Methods-Diagnosed Incident Cases of Sepsis 59

4.4.3 Forecast Assumptions and Methods-Sepsis Mortality Cases 61

4.4.4 Forecast Assumptions and Methods-Diagnosed Incident Cases of Sepsis by Severity 62

4.4.5 Forecast Assumptions and Methods-Sepsis Mortality Cases by Severity 63

4.4.6 Forecast Assumptions and Methods-Diagnosed Incident Cases of Sepsis by Causative Organism 64

4.4.7 Forecast Assumptions and Methods-Sepsis Mortality Cases by Causative Pathogen 66

4.4.8 Forecast Assumptions and Methods-Diagnosed Incident Cases of Sepsis by Comorbid Condition 67

4.5 Epidemiological Forecast for Sepsis (2013-2023) 69

4.5.1 Diagnosed Incident Cases of Sepsis 69

4.5.2 Age-Specific Diagnosed Incident Cases of Sepsis 70

4.5.3 Sex-Specific Diagnosed Incident Cases of Sepsis 72

4.5.4 Sepsis Mortality Cases 75

4.5.5 Age-Specific Sepsis Mortality Cases 77

4.5.6 Sex-Specific Sepsis Mortality Cases 79

4.5.7 Diagnosed Incident Cases of Sepsis by Severity 81

4.5.8 Sepsis Mortality Cases by Severity 83

4.5.9 Diagnosed Incident Cases of Sepsis by Causative Organism 85

4.5.10 Sepsis Mortality Cases by Causative Organism 87

4.5.11 Diagnosed Incident Cases of Sepsis with a Comorbid Condition 89

4.6 Discussion 91

4.6.1 Epidemiological Forecast Insight 91

4.6.2 Limitations of the Analysis 91

4.6.3 Strengths of the Analysis 93

5 Current Treatment Options 94

5.1 Overview 94

5.2 Treatment Bundles 97

5.3 Pathogen-Targeting Approaches to Treating Sepsis 100

5.3.1 Antimicrobial Therapy 100

5.3.2 Other Therapies-Antivirals, Antifungals and Antiparasitics 104

5.4 Host-Targeting Approaches to Treating Sepsis 105

5.4.1 Overview of Current Supportive Care 105

5.5 Country Differences 110

6 Unmet Needs Assessment and Opportunity Analysis 112

6.1 Overview 112

6.2 Unmet Needs Analysis 114

6.2.1 Unmet Need: Sepsis-Specific Therapies 114

6.2.2 Unmet Need: An Improved Understanding of Sepsis Pathophysiology 115

6.2.3 Unmet Need: Clinically Relevant Biomarkers to Guide Clinical Trial Enrollment and Inform Physician Treatment Decisions 116

6.2.4 Unmet Need: Rapid, Accurate, and Sensitive Diagnostic Tools 118

6.2.5 Unmet Need: Refined Sepsis Definitions and Diagnoses 119

6.2.6 Unmet Need: Improved Sepsis Education and Awareness for the Public and Healthcare Professionals 121

6.3 Opportunity Analysis 123

6.3.1 Opportunity: Develop Innovative Immunomodulatory Agents that Target Sepsis-Specific Pathophysiology 123

6.3.2 Opportunity: Improved Supportive Care for Sepsis-Induced Comorbidities and Combination Therapies 125

6.3.3 Opportunity: Identify and Leverage Novel Biomarkers to Streamline Patient Identification and Better Demonstrate Efficacy 127

6.3.4 Opportunity: Leverage Diagnostics to Help Streamline Clinical Development and Improve Patient Care 128

6.3.5 Opportunity: Recruit Experts to Improve Company Insight on Sepsis Pathophysiology 130

6.3.6 Opportunity: Implement Sepsis Awareness Campaigns and Roll Out Educational Tools for Healthcare Professionals 131

7 Research and Development Strategies 134

7.1 Overview 134

7.2 Approaches to Sepsis-specific Therapy Development 136

7.2.1 Novel Targets 136

7.2.2 Immunomodulatory Agents 137

7.2.3 Leverage Novel Biomarkers and Companion Diagnostics 138

7.2.4 Solve Funding Issues and Potential Partnerships 140

7.3 Clinical Trial Design 142

7.3.1 Current Clinical Trial Design 144

7.3.2 Accurate and Efficient Patient Selection and Enrollment Criteria 149

7.3.3 Alternative Efficacy Endpoints 154

7.3.4 Biomarker-Driven Adaptive Design Trials 157

7.3.5 Standardization of Background Care in Multicenter Trials 158

8 Pipeline Assessment 160

8.1 Overview 160

8.2 Promising Products in Late-Stage Clinical Development 162

8.2.1 ART-123 162

8.2.2 Toraymyxin 170

8.3 Promising Products in Early-Stage Clinical Development 180

8.3.1 Selepressin 181

8.3.2 ALT-836 184

8.3.3 LB-1148 188

8.3.4 recAP 192

8.3.5 IFX-1 198

8.3.6 Other Innovative Early-Stage Approaches 201

8.4 Products in Preclinical Development 207

9 Pipeline Valuation Analysis 209

9.1 Clinical Benchmark of Key Pipeline Therapies 209

9.2 Commercial Benchmark of Key Pipeline Therapies 211

9.3 Competitive Assessment 214

9.4 Top-Line Five-Year Forecast 216

9.4.1 US 219

9.4.2 5EU 221

10 Appendix 224

10.1 Bibliography 224

10.2 Abbreviations 236

10.3 Methodology 240

10.4 Forecasting Methodology 240

10.4.1 Sepsis Patient Population Segmentation 240

10.4.2 Percent Product-Treated Patients 241

10.4.3 Products Included in Each Therapeutic Class 242

10.4.4 Product Launch Dates 243

10.4.5 General Pricing Assumptions 243

10.4.6 Individual Product Assumptions 244

10.4.7 Pricing of Pipeline Products 247

10.5 Physicians and Specialists Included in this Study 250

10.6 About the Authors 252

10.6.1 Analyst 252

10.6.2 Epidemiologist 252

10.6.3 Therapy Area Director 253

10.6.4 Global Head of Healthcare 253

10.7 About GlobalData 254

10.8 Disclaimer 254

1.2 List of Figures

Figure 1: Pathogens Responsible for Causing Sepsis, Severe Sepsis, and Septic Shock 25

Figure 2: The Diagnostic Pathway for SIRS, Sepsis, Severe Sepsis, and Septic Shock 26

Figure 3: Common Causes and Origins of Sepsis 27

Figure 4: Effects of Excessive Specific Mediators on the Host Immune System 31

Figure 5: Competing Theories of the Host Immune Response-the Inflammatory and Anti-inflammatory Response 35

Figure 6: International Treatment Algorithm Overview for Sepsis, Severe Sepsis, and Septic Shock 40

Figure 7: 6MM, Diagnosed Incident Cases of Sepsis, All Ages, Both Sexes, N, 2013-2023 70

Figure 8: 6MM, Diagnosed Incident Cases of Sepsis, by Age, Both Sexes, N, 2013 72

Figure 9: 6MM, Diagnosed Incident Cases of Sepsis, by Sex, All Ages, N, 2013 74

Figure 10: 6MM, Sepsis Mortality Cases, All Ages, Both Sexes, N, 2013-2023 76

Figure 11: 6MM, Sepsis Mortality Cases, by Age, Both Sexes, N, 2013 78

Figure 12: 6MM, Sepsis Mortality Cases, by Sex, All Ages, N, 2013 80

Figure 13: 6MM, Diagnosed Incident Cases of Sepsis by Severity, All Ages, Both Sexes, N, 2013 82

Figure 14: 6MM, Sepsis Mortality Cases by Severity, All Ages, Both Sexes, N, 2013 84

Figure 15: 6MM, Diagnosed Incident Cases of Sepsis by Causative Organism, All Ages, Both Sexes, N, 2013 86

Figure 16: 6MM, Sepsis Mortality Cases by Causative Organism, All Ages, Both Sexes, N, 2013 88

Figure 17: 6MM, Diagnosed Incident Cases of Sepsis with a Comorbid Condition, All Ages, Both Sexes, N, 2013 90

Figure 18: Current Treatment Options for Sepsis, Severe Sepsis, and Septic Shock 95

Figure 19: Competitive Assessment of Sepsis Pipeline Products, 2016-2021 215

Figure 20: Global Sales for Sepsis Products by Region, 2016-2021 217

Figure 21: US Sales for Sepsis Products, 2016-2021 220

Figure 22: 5EU Sales for Sepsis Products, 2016-2021 222

1.1 List of Tables

Table 1: Summary of Temporal Pathophysiological Events Causing Sepsis 29

Table 2: Mediators of the Pro-inflammatory and Anti-inflammatory responses 30

Table 3: Major Biological Events Characteristic to the Hyper-inflammatory Response 32

Table 4: Major Biological Events Characteristic to the Excessive Anti-inflammatory Response 33

Table 5: Symptoms Associated with SIRS, Sepsis, Severe Sepsis, and Septic Shock 36

Table 6: SIRS, Sepsis, Severe Sepsis, and Septic Shock Diagnostic Criteria 38

Table 7: Guidelines for Stratification of Patients with SIRS, Sepsis, Severe Sepsis, and Septic Shock 41

Table 8: Common Comorbidities within Sepsis Patients 43

Table 9: Comorbid Conditions of Sepsis 46

Table 10: ACCP/SCCM Criteria for Classification of Sepsis by Severity 48

Table 11: 6MM, Sources of Diagnosed Incidence Data of Sepsis 49

Table 12: 6MM, Sources of Mortality Data of Sepsis 49

Table 13: 6MM, Sources of Diagnosed Incidence Data of Sepsis by Severity 50

Table 14: 6MM, Sources of Mortality Data of Sepsis by Severity 50

Table 15: 6MM, Sources of Diagnosed Incidence Data of Sepsis by Causative Organism 51

Table 16: 6MM, Sources of Mortality Data of Sepsis by Causative Organism 51

Table 17: 6MM, Sources of Diagnosed Incident Cases of Sepsis with DIC 51

Table 18: 6MM, Sources of Diagnosed Incident Cases of Sepsis with ARDS 52

Table 19: 6MM, Sources of Diagnosed Incident Cases of Sepsis with ALI 52

Table 20: 6MM, Sources of Diagnosed Incident Cases of Sepsis with AKI 52

Table 21: 6MM, Diagnosed Incident Cases of Sepsis, All Ages, Both Sexes, N, 2013-2023 69

Table 22: 6MM, Diagnosed Incident Cases of Sepsis, by Age, Both Sexes, N, (Row %), 2013 71

Table 23: 6MM, Diagnosed Incident Cases of Sepsis, by Sex, All Ages, N (Row %), 2013 73

Table 24: 6MM, Sepsis Mortality Cases, All Ages, Both Sexes, N, 2013-2023 75

Table 25: 6MM, Sepsis Mortality Cases, by Age, Both Sexes, N, (Row %), 2013 77

Table 26: 6MM, Sepsis Mortality Cases, by Sex, All Ages, N (Row %), 2013 79

Table 27: 6MM, Diagnosed Incident Cases of Sepsis by Severity, All Ages, Both Sexes, N (Row %), 2013 81

Table 28: 6MM, Sepsis Mortality Cases by Severity, All Ages, Both Sexes, N, (Row %), 2013 83

Table 29: 6MM, Diagnosed Incident Cases of Sepsis by Causative Organism, All Ages, Both Sexes, N (Row %), 2013 85

Table 30: 6MM, Sepsis Mortality Cases by Causative Organism, All Ages, Both Sexes, N (Row %), 2013 87

Table 31: 6MM, Diagnosed Incident Cases of Sepsis with a Comorbid Condition, All Ages, Both Sexes, N, 2013 89

Table 32: Treatment Bundles for Sepsis Patients 98

Table 33: Commonly Used Antibiotics in Sepsis and Important Gaps in Coverage 102

Table 34: Other Supportive Therapies to be Implemented When Clinically Relevant 106

Table 35: Unmet Need and Opportunity in Sepsis 113

Table 36: Recent High-Profile Failures in the Sepsis Market 134

Table 37: Key Companies in the Sepsis Market, 2014 142

Table 38: Design of Pipeline Clinical Trials in Sepsis 146

Table 39: Sepsis Therapies-Late-Stage Pipeline, 2014 161

Table 40: Product Profile-ART-123 164

Table 41: ART-123 Phase IIb Trial Summary of 28-Day Mortality Rates by Overall Patients and Subgroups 166

Table 42: ART-123 Phase IIb Trial Event-Free and Alive Days 166

Table 43: ART-123 Phase IIb Trial Important Treatment Emergent AEs and SAEs Monitored 168

Table 44: ART-123 SWOT Analysis, 2015 169

Table 45: Product Profile-Toraymyxin 173

Table 46: EUPHAS Trial-Toraymyxin Physiological End Points by Treatment Group at Baseline and 72 Hours 177

Table 47: EUPHAS Trial-Change in SOFA Scores by Treatment Group After 72 hours 177

Table 48: EUPHAS Trial-Event-free Days and Days Spent in Hospital by Treatment Group 177

Table 49: Toraymyxin SWOT Analysis, 2014 179

Table 50: Sepsis Therapies-Innovative Early-Stage Approaches, 2015 180

Table 51: Product Profile-Selepressin 182

Table 52: Product Profile-ALT-836 186

Table 53: Hospital Indices-ALT-836 187

Table 54: Safety Profile-ALT-836 188

Table 55: Product Profile-LB-1148 190

Table 56: Product Profile-recAP 194

Table 57: Safety Profile of BIAP 197

Table 58: Product Profile-IFX-1 200

Table 59: Product Profile-Levosimendan 203

Table 60: Product Profile-Cx-611 206

Table 61: Sepsis Products in Preclinical Development, 2014 207

Table 62: Clinical Benchmark of Key Sepsis Pipeline Products, 2016-2021 210

Table 63: Commercial Benchmark of Key Sepsis Pipeline Products, 2016-2021 212

Table 64: Top-Line Sales Forecasts (USD m) for Sepsis Pipeline Products, 2016-2021 217

Table 65: Key Events Impacting Sales for Sepsis Products, 2016-2021 218

Table 66: Sepsis Products Market-Drivers and Barriers, 2016-2021 219

Table 67: Sepsis Patient Population Segmentation-Secondary Sources Leveraged 241

Table 68: Patient Populations Targeted by Sepsis Pipeline Product Developers 242

Table 69: Sepsis Pipeline Products Broken Down by Therapeutic Class 242

Table 70: Key Product Launch Dates by Region 243

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com